Infinity Pharmaceuticals Inc (OTCPK:INFIQ)

$ 0.0001 0 (0%) Market Cap: 9,000.00 Enterprise Value: -17.10 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Infinity Pharmaceuticals Inc and MEI Pharma Inc Merger Agreement Call - Pre-recorded Transcript
Jun 19, 2023
Infinity Pharmaceuticals Inc and MEI Pharma Inc Merger Agreement Call Transcript
Feb 23, 2023
Q3 2022 Infinity Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2022

$0.7402 (-37.80%)

Earnings
Q2 2022 Infinity Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2022

$0.74 (-8.56%)

Earnings
Q1 2022 Infinity Pharmaceuticals Inc Earnings Call Transcript
May 03, 2022

$0.84 (+6.99%)

Earnings
Q4 2021 Infinity Pharmaceuticals Inc Earnings Call Transcript
Mar 29, 2022

$0.9953 (+0.52%)

Earnings
Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Infinity Pharmaceuticals Inc at 2021 San Antonio Breast Cancer Symposium - Conference Call Transcript
Dec 10, 2021
Q3 2021 Infinity Pharmaceuticals Inc Earnings Call Transcript
Nov 02, 2021

$2.63 (-0.38%)

Earnings
Infinity Pharmaceuticals Inc KOL Webinar to Discuss MARIO-3 and MARIO-275 Phase 2 Trials Transcript
Jul 27, 2021
Q1 2021 Infinity Pharmaceuticals Inc Earnings Call Transcript
May 13, 2021

$2.66 (-5.67%)

Earnings
Q4 2020 Infinity Pharmaceuticals Inc Earnings Call Transcript
Mar 16, 2021

$3.1 (-3.73%)

Earnings
Infinity Pharmaceuticals Inc to Discuss Clinical Data from MARIO-275 - Conference Call Transcript
Feb 11, 2021
Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Infinity Pharmaceuticals Inc at 2020 San Antonio Breast Cancer Symposium - Conference Call Transcript
Dec 09, 2020
Q3 2020 Infinity Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2020

$1.15 (+1.77%)

Earnings
Q2 2020 Infinity Pharmaceuticals Inc Earnings Call Transcript
Jul 30, 2020

$0.8282 (+0.39%)

Earnings
Q1 2020 Infinity Pharmaceuticals Inc Earnings Call Transcript
May 11, 2020

$1.01 (-9.01%)

Earnings
Q4 2019 Infinity Pharmaceuticals Inc Earnings Call Transcript
Mar 03, 2020

$1.1 (-6.78%)

Earnings
Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Q3 2019 Infinity Pharmaceuticals Inc Earnings Call Transcript
Oct 30, 2019

$1.02 (-3.77%)

Earnings
Q2 2019 Infinity Pharmaceuticals Inc Earnings Call Transcript
Jul 30, 2019

$1.57 (-1.26%)

Earnings
Q1 2019 Infinity Pharmaceuticals Inc Earnings Call Transcript
May 07, 2019

$1.7 (-0.58%)

Earnings
Q4 2018 Infinity Pharmaceuticals Inc Earnings Call Transcript
Mar 14, 2019

$1.91 (+24.03%)

Earnings

Infinity Pharmaceuticals Inc to Discuss Clinical Data from MARIO-275 - Conference Call Transcript

Feb 11, 2021 / 12:30PM GMT

Release Date Price: $4.47 (+13.16%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Infinity Pharmaceuticals ASCO Genitourinary Cancers Symposium Call.

(Operator Instructions)

Please be advised that today's conference is being recorded. (Operator Instructions)

I would now hand the conference over to your host today, Jayne Kauffman. Please go ahead.

Jayne Kauffman

Infinity Pharmaceuticals, Inc. - Senior Executive Coordinator

Good morning, everyone, and welcome to today's call where we will review data from MARIO-275, which was presented today during the ASCO Genitourinary Cancer Symposium, or ASCO GU.

Participants on today's call are Adelene Perkins, Chief Executive Officer; and Dr. Brian Schwartz, Consulting Chief Physician from Infinity Pharmaceuticals.

During this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and financial projections. Our actual results may differ

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.